clinical trial · NCT07726888
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis
Second Affiliated Hospital of Wenzhou Medical University·—·recruiting·n = 97
Ulcerative Colitis (Disorder)GuselkumabGuselkumab
brief summary
In a real-world setting, this study systematically evaluates the clinical efficacy and safety of guselkumab (GUS) in the treatment of ulcerative colitis (UC), encompassing multi-dimensional outcomes including clinical remission, biochemical remission, endoscopic remission, histologic healing, and intestinal ultrasound changes.
started
Jul 31, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Aug 19, 2026
official title
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis:A Real-World Prospective Cohort Study.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol